Pharvaris (PVHS) said the U.S. FDA accepted its New Drug Application for Deucrictibant immediate-release (IR) capsule (20 mg) for on-demand treatment of Hereditary Angioedema. NDA acceptance is a positive regulatory milestone that can advance the review timeline, supporting expectations for potential future approval. No efficacy/safety or approval date details were provided in the excerpt.
Pharvaris (PVHS) said the U.S. FDA accepted its New Drug Application for Deucrictibant immediate-release (IR) capsule (20 mg) for on-demand treatment of Hereditary Angioedema. NDA acceptance is a positive regulatory milestone that can advance the review timeline, supporting expectations for potential future approval. No efficacy/safety or approval date details were provided in the excerpt.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
